Evidence map›Paper›PMID 41053142›Full record

ArticleCell death & disease2025

IRE1α translational suppression potentiates STING-dependent chemoresistance in pancreatic cancer.

Yuan Luo, Mengqi Sun, Lei Chang, Zinan He, Xinghang Zhou, Yaming Yuan, Huijuan Sun, Shiqi Luo, Jinyan Huang, Hongkun Wu and 5 more

Abstract read
In one paragraph

Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Chemotherapy in combination with KRAS inhibitors inJournal of thoracic disease · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yuan Luo *Zhejiang Provincial Key Laboratory of Pancreatic Disease, MOE Joint International Research Laboratory of Pancreatic Diseases & Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. luoyuan715@126.com.ORCID http://orcid.org/0009-0008-5633-409X
Mengqi Sun *Zhejiang Provincial Key Laboratory of Pancreatic Disease, MOE Joint International Research Laboratory of Pancreatic Diseases & Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Lei Chang *Zhejiang Provincial Key Laboratory of Pancreatic Disease, MOE Joint International Research Laboratory of Pancreatic Diseases & Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Zinan HeKey Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education) & Department of Infectious Diseases of the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Xinghang ZhouZhejiang Provincial Key Laboratory of Pancreatic Disease, MOE Joint International Research Laboratory of Pancreatic Diseases & Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yaming YuanShanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China.
Huijuan SunShanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China.
Shiqi LuoDepartment of Urology of the Second Affiliated Hospital, Liangzhu Laboratory, School of Medicine, Zhejiang University, Hangzhou, China.
Jinyan HuangZhejiang Provincial Key Laboratory of Pancreatic Disease, MOE Joint International Research Laboratory of Pancreatic Diseases & Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID http://orcid.org/0000-0002-8053-0209
Hongkun WuZhejiang Provincial Key Laboratory of Pancreatic Disease, MOE Joint International Research Laboratory of Pancreatic Diseases & Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Wenjun LiuZhejiang Provincial Key Laboratory of Pancreatic Disease, MOE Joint International Research Laboratory of Pancreatic Diseases & Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Zhangsen ZhouShanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China.
Yuanhui MaoDepartment of Urology of the Second Affiliated Hospital, Liangzhu Laboratory, School of Medicine, Zhejiang University, Hangzhou, China.ORCID http://orcid.org/0000-0002-0893-2588
Yewei JiZhejiang Provincial Key Laboratory of Pancreatic Disease, MOE Joint International Research Laboratory of Pancreatic Diseases & Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. ywji@cqmu.edu.cn.ORCID http://orcid.org/0000-0003-4960-9928
Tingbo LiangZhejiang Provincial Key Laboratory of Pancreatic Disease, MOE Joint International Research Laboratory of Pancreatic Diseases & Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. liangtingbo@zju.edu.cn.ORCID http://orcid.org/0000-0003-0143-3353

Funding

National Natural Science Foundation of China (National Science Foundation of China) 32370585National Natural Science Foundation of China (National Science Foundation of China) 32371208National Natural Science Foundation of China (National Science Foundation of China) 82171731, 82371737National Natural Science Foundation of China (National Science Foundation of China) 82188102National Natural Science Foundation of China (National Science Foundation of China) 82303596Natural Science Foundation of Shanghai (Natural Science Foundation of Shanghai Municipality) 23ZR1475600
6 · The paper itself

Abstract

Chemotherapy remains a standard treatment for pancreatic ductal adenocarcinoma (PDAC); however, its effectiveness is limited, and the underlying mechanisms are poorly understood. STING plays diverse and critical roles in cancer, yet the role of PDAC cell-intrinsic STING signaling and its regulation under chemotherapy remain unclear. Here, we report that chemotherapy induces cancer cell-intrinsic STING signaling and that STING deletion in PDAC enhances cell death under chemotherapy while suppressing tumor growth in both immune-deficient and immune-competent mice. Interestingly, chemotherapy selectively inhibits translation of IRE1α, an ER membrane protein and a canonical mediator of ER stress. Loss of IRE1α in PDAC amplifies STING signaling and increases resistance to chemotherapy. Mechanistically, IRE1α interacts with STING via their transmembrane regions, reducing STING stability in PDAC cells. Our study reveals that PDAC cells downregulate IRE1α to reinforce STING-mediated pro-survival response; however, this adaptation also makes them more vulnerable to proteostasis imbalance and ER stress-induced cell death. Notably, we demonstrate that combining ER stress inducers with STING signaling inhibition enhances chemotherapy efficacy both in vitro and in vivo.

Indexed as

Carcinoma, Pancreatic DuctalDrug Resistance, NeoplasmEndoribonucleasesMembrane ProteinsPancreatic NeoplasmsProtein Serine-Threonine KinasesAnimalsCell Line, TumorEndoplasmic Reticulum StressHumansMiceProtein BiosynthesisSignal TransductionSTING ProteinEndoribonucleasesERN1 protein, humanMembrane ProteinsProtein Serine-Threonine KinasesSTING1 protein, humanSting1 protein, mouseSTING Protein

Identifiers

PMID41053142
PMCPMC12501023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.